Featured Research

from universities, journals, and other organizations

Cancer risk the same for kidney transplant recipients, no matter the drug, study finds

Date:
May 4, 2010
Source:
American Society of Nephrology
Summary:
Drugs taken by kidney transplant recipients to prevent organ rejection carry similar risks of cancer, according to a new study. The results suggest that no single medication is to blame for the higher incidence of cancer seen among patients who have undergone transplantation.

Drugs taken by kidney transplant recipients to prevent organ rejection carry similar risks of cancer, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results suggest that no single medication is to blame for the higher incidence of cancer seen among patients who have undergone transplantation.

Individuals who receive a kidney transplant have an increased risk of developing cancer compared with the general population. Researchers suspected that the increased risk may come from immunosuppressive medications that patients must take long-term to prevent organ rejection. To investigate, Martin Gallagher, MBBS, FRACP (The George Institute for International Health in Australia) and his colleagues studied the incidence of cancer in transplant patients who took part in a randomized clinical trial 20 years ago, looking for any differences in cancer risk associated with different immunosuppressive drugs.

The researchers studied the incidence of cancer among 481 kidney transplant recipients in the Australian Multicentre Trial of Cyclosporine Withdrawal who each received one of three treatment regimens: azathioprine and prednisolone, cyclosporine monotherapy, or cyclosporine monotherapy followed by a switch to azathioprine and prednisolone after three months.

A total of 226 patients in the trial developed at least one cancer. By 20 years post transplant, 27% of patients developed non-skin cancer and 48% of patients developed skin cancer. One type of treatment did not have a greater effect on cancer timing or incidence than another, indicating that the therapies carry similar risks for cancer after kidney transplantation.

"We have shown no significant differences with a high degree of precision, allowing us to conclude that any differences in cancer risk from these different treatments are unlikely to be clinically significant," said Dr. Gallagher. He added that this study provides the strongest evidence yet that no single immunosuppressive medication appears to drive the increase in cancer risk seen after transplantation.

The study also indicates that certain patient characteristics that are known at the time of transplantation have a significant effect on recipients' increased risk of cancer. (Non-skin cancer was associated with increasing age and previous smoking history; skin cancer was associated with increasing age, non-brown eye color, fairer skin, and a functioning transplant.) Therefore, patients at especially high risk can be monitored more closely and use preventive measures to protect against cancer.

The authors noted that immune suppressive treatments have evolved since the trial was designed 20 years ago. It is likely that today's immunosuppressive regimens, which are better at preventing acute rejection, are more potent at immunosuppression.

Study co-authors include Meg Jardine, MBBS, PhD, FRACP, Vlado Perkovic, MBBS, PhD, FRACP, Alan Cass, MBBS, PhD, FRACP (The George Institute for International Health); Patrick Kelly, PhD, Jonathan Craig, MBBS, PhD (University of Sydney, in Australia); Josette Eris, MBBS, PhD, FRACP (Royal Prince Alfred Hospital, in Camperdown, Australia); and Angela Webster, MBBS, PhD, MRCP (University of Sydney and Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, in Adelaide, South Australia).

Disclosures: Dr. Gallagher and Dr. Perkovic have received speaking fees from Roche Pharmaceuticals. Dr. Eris has received travel assistance from and chairs advisory boards of Roche (chair), Novartis, Wyeth, and Janssen-Cilag; she has also received travel support from Novartis and Roche within the last three years. The ANZDATA Registry has received contributions from Roche, Wyeth and Novartis.


Story Source:

The above story is based on materials provided by American Society of Nephrology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Martin P. Gallagher, Patrick J. Kelly, Meg Jardine, Vlado Perkovic, Alan Cass, Jonathan C. Craig, Josette Eris, and Angela C. Webster. Long-Term Cancer Risk of Immunosuppressive Regimens after Kidney Transplantation. Journal of the American Society Nephrology, 2010; DOI: 10.1681/ASN.2009101043

Cite This Page:

American Society of Nephrology. "Cancer risk the same for kidney transplant recipients, no matter the drug, study finds." ScienceDaily. ScienceDaily, 4 May 2010. <www.sciencedaily.com/releases/2010/04/100429172952.htm>.
American Society of Nephrology. (2010, May 4). Cancer risk the same for kidney transplant recipients, no matter the drug, study finds. ScienceDaily. Retrieved October 23, 2014 from www.sciencedaily.com/releases/2010/04/100429172952.htm
American Society of Nephrology. "Cancer risk the same for kidney transplant recipients, no matter the drug, study finds." ScienceDaily. www.sciencedaily.com/releases/2010/04/100429172952.htm (accessed October 23, 2014).

Share This



More Health & Medicine News

Thursday, October 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
US to Track Everyone Coming from Ebola Nations

US to Track Everyone Coming from Ebola Nations

AP (Oct. 22, 2014) Stepping up their vigilance against Ebola, federal authorities said Wednesday that everyone traveling into the US from Ebola-stricken nations will be monitored for symptoms for 21 days. (Oct. 22) Video provided by AP
Powered by NewsLook.com
Doctors Help Paralysed Man Walk Again, Patient in Disbelief

Doctors Help Paralysed Man Walk Again, Patient in Disbelief

AFP (Oct. 22, 2014) Polish doctors describe how they helped a paralysed man walk again, with the patient in disbelief at the return of sensation to his legs. Duration: 1:04 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins